Perrigo Company plc (PRGO) Income Statement

The consistent quarterly revenue declines, ranging from -0.9% to -10.7% year-over-year, indicate a structural issue rather than a temporary blip. The lack of any growth quarter in the provided period suggests that the company may be losing market share or facing pricing pressure in its generic and specialty drug segments. Investors should monitor whether new product launches or cost rationalization can reverse this trend.

The gross margin decline is significant and appears to be accelerating, with the most recent quarter showing the lowest margin in the series. This could reflect increased competition in generics, higher input costs, or a shift toward lower-margin products. The peer comparison shows Haleon and Prestige Consumer Healthcare with gross margins above 50%, highlighting Perrigo's relative weakness. If this trend continues, it will further pressure operating income and cash flow.

The operating margin has been volatile, with negative operating income in 2024Q1 and 2024Q2, and a sharp recovery in 2025Q4 due to a negative SG&A figure, which appears to be an anomaly. The recent quarters show operating income barely positive, suggesting that the company's cost structure is too heavy for its current revenue base. This implies that without significant cost cuts or revenue growth, operating leverage will remain negative.

The extreme volatility in SG&A, including a negative expense in 2025Q4, suggests that the line item includes significant non-recurring items such as legal settlements or asset write-downs. Excluding that anomaly, SG&A has generally been in the $220M-$300M range, which appears high relative to revenue, contributing to thin operating margins. Management's ability to control these costs will be critical to improving profitability.